Assignee
SYNDEVRX INC
US·18 granted patents·10 pending applications·134 citations·filing 2014–2025
Top patents by PatentIndex Score
28 records- 0197US10010544B2METAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2017·Granted Jul 3, 2018·11 cites·50 claims
- 0297US9730955B2Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2016·Granted Aug 15, 2017·10 cites·10 claims
- 0397US9585909B2Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2016·Granted Mar 7, 2017·10 cites·10 claims
- 0496US10159692B2Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2017·Granted Dec 25, 2018·8 cites·2 claims
- 0596US9173956B2METAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2014·Granted Nov 3, 2015·22 cites·59 claims
- 0695US11304944B2MetAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2020·Granted Apr 19, 2022·3 cites·42 claims
- 0795US9757373B2MetAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2016·Granted Sep 12, 2017·13 cites·58 claims
- 0895US9750737B2METAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2016·Granted Sep 5, 2017·11 cites·51 claims
- 0995US9433600B2METAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2015·Granted Sep 6, 2016·15 cites·51 claims
- 1094US11273142B2Treatment for tumors driven by metabolic dysfunctionSYNDEVRX INC·Filed 2020·Granted Mar 15, 2022·4 cites·38 claims
- 1191US11612577B2Biomarkers of METAP2 inhibitors and applications thereofSYNDEVRX INC·Filed 2019·Granted Mar 28, 2023·4 cites·14 claims
- 1290US9969722B2Fumagillol derivatives and polymorphs thereofSYNDEVRX INC·Filed 2016·Granted May 15, 2018·7 cites·18 claims
- 1389US10646463B2Treatment for tumors driven by metabolic dysfunctionSYNDEVRX INC·Filed 2017·Granted May 12, 2020·4 cites·38 claims
- 1489US10588904B2METAP2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2018·Granted Mar 17, 2020·4 cites·47 claims
- 1588US9895449B2Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2016·Granted Feb 20, 2018·4 cites·35 claims
- 1688US2023165892A1Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2022·Application pending·0 cites
- 1787US10287277B2Fumagillol derivatives and polymorphs thereofSYNDEVRX INC·Filed 2018·Granted May 14, 2019·4 cites·11 claims
- 1884US2026076960A1Metap2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2025·Application pending·0 cites
- 1982US2023048989A1Metap2 inhibitors and methods of treating obesitySYNDEVRX INC·Filed 2022·Application pending·0 cites
- 2080US2025387350A1Biomarkers of metap2 inhibitors and applications thereofSYNDEVRX INC·Filed 2025·Application pending·0 cites
- 2178US12419846B2Biomarkers of METAP2 inhibitors and applications thereofSYNDEVRX INC·Filed 2023·Granted Sep 23, 2025·0 cites·17 claims
- 2277US10722532B2Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2018·Granted Jul 28, 2020·0 cites·11 claims
- 2377US2025288606A1Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2025·Application pending·0 cites
- 2474US2021128607A1Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereofSYNDEVRX INC·Filed 2020·Application pending·0 cites
- 2571US2022280470A1Treatment for tumors driven by metabolic dysfuctionSYNDEVRX INC·Filed 2022·Application pending·0 cites
- 2670US2015141580A1Optimized drug conjugatesSYNDEVRX INC·Filed 2014·Application pending·0 cites
- 2763US2026014194A1Combinations comprising metap2 inhibitors for the treatment of cancerSYNDEVRX INC·Filed 2023·Application pending·0 cites
- 2857US2023404963A1Combinations of metap2 inhibitors and cd4/6 inhibitors for the treatment of cancerSYNDEVRX INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SYNDEVRX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →